MG-262 (Z-Leu-Leu-Leu-B(OH)2): A Potent, Reversible Proteasome Inhibitor for Precision Cell Biology

Executive Summary: MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a potent, reversible, and cell-permeable inhibitor of proteasome chymotryptic activity, with an IC50 of 122 nM under defined in vitro conditions (APExBIO). The compound's boronic acid peptide structure enables selective, reversible inhibition, facilitating precise modulation of the ubiquitin-proteasome system (UPS) in living cells. MG-262 is highly soluble in DMSO (≥24.57 mg/mL) and ethanol (≥96.4 mg/mL), but not in water, requiring strict handling and storage at –20°C. In cellular and animal models, MG-262 has been validated for inducing apoptosis, cell cycle arrest, and inhibition of osteoclast differentiation, establishing its value in cancer, inflammatory, and neurodegenerative research (Nature Metabolism, 2025). APExBIO provides detailed protocols and quality assurance for research reproducibility.

Biological Rationale

The ubiquitin-proteasome system (UPS) is essential for regulated protein degradation in eukaryotic cells. Proteasomes degrade polyubiquitinated proteins, maintaining cellular proteostasis and controlling key processes including cell cycle progression, apoptosis, and stress responses (Nature Metabolism, 2025). Dysregulation of proteasome function contributes to muscle wasting, cancer, and neurodegeneration. The chymotryptic activity of the proteasome, primarily mediated by its β5 subunit, is a validated drug target in oncology and cell biology. Inhibitors such as MG-262 provide a reversible, tunable approach to interrogate proteasome function in vitro and in vivo.

Mechanism of Action of MG-262 (Z-Leu-Leu-Leu-B(OH)2)

MG-262 is a boronic peptide acid that reversibly binds the proteasome β5 subunit, selectively inhibiting chymotryptic-like activity. This inhibition is competitive and reversible, enabling precise temporal control in cell-based assays. The boronic acid moiety forms a covalent, yet reversible, adduct with the active site threonine of the proteasome catalytic core (APExBIO). This mechanism underlies the compound’s specificity and its ability to modulate proteasome-dependent degradation of regulatory proteins such as cyclins, p21, and p27. Loss of proteasome function via MG-262 leads to accumulation of cell cycle inhibitors, cell growth arrest, and induction of apoptosis pathways—specifically mitochondrial membrane depolarization, caspase-3 activation, and poly(ADP-ribose) polymerase cleavage (Nature Metabolism, 2025).

Evidence & Benchmarks

• MG-262 inhibits proteasome chymotryptic activity with an IC50 of 122 nM in biochemical assays (APExBIO).
• In human nasal mucosa and polyp fibroblasts, MG-262 induces cell growth arrest, blocks DNA replication, and increases p21/p27 expression at concentrations as low as 100 nM (Nature Metabolism, 2025).
• MG-262 triggers apoptosis by loss of mitochondrial membrane potential, caspase-3 activation, and PARP cleavage within 24 hours of treatment in vitro (Nature Metabolism, 2025).
• In osteoclastogenesis assays, MG-262 inhibits differentiation in a dose-dependent manner, with effects measurable at 10–100 nM (Nature Metabolism, 2025).
• Intravenous administration in mice reduces proteasome activity across multiple organs, confirming in vivo bioactivity (Nature Metabolism, 2025).
• Compared to irreversible inhibitors, MG-262 allows reversible, time-resolved proteasome inhibition, minimizing off-target effects (MG-262 Thought Leadership).

This article extends the mechanistic depth found in MG-262: Reversible, Cell-Permeable Proteasome Inhibitor for Apoptosis Research by providing explicit IC50 benchmarks, validated solubility data, and workflow integration strategies for disease modeling. For further discussion on translational design, see MG-262: Translating Reversible Proteasome Inhibition, which contextualizes MG-262’s impact on clinical research. For autophagy and aging-focused applications, MG-262: Unveiling Proteasome Inhibitor Applications in Muscle Homeostasis discusses complementary mechanisms.

Applications, Limits & Misconceptions

MG-262 is widely used in:

• Proteasome inhibition assays for functional genomics and pathway analysis.
• Cell cycle arrest studies, including quantification of p21/p27 accumulation.
• Apoptosis research in cancer, inflammatory, and neurodegenerative disease models.
• Osteoclast differentiation inhibition for bone biology.
• In vivo modulation of proteasome activity for animal models.

Common Pitfalls or Misconceptions

• MG-262 is not water-soluble; dissolution must be in DMSO or ethanol (≥24.57 mg/mL and ≥96.4 mg/mL, respectively).
• Compound is unstable in solution; prepare fresh aliquots immediately before use and store at –20°C.
• MG-262 selectively inhibits chymotryptic activity but does not fully block all proteasome functions—other activities (tryptic/caspase-like) may persist.
• IC50 values are assay- and cell type-dependent; always calibrate dose-response in each experimental system.
• MG-262 is not a direct autophagy inhibitor; it modulates proteostasis primarily via the proteasome, not lysosomal degradation pathways.

Workflow Integration & Parameters

For optimal use, dissolve MG-262 in DMSO or ethanol at the recommended concentrations. Prepare fresh working solutions immediately prior to application. Store both powder and stock solutions at –20°C, avoiding freeze-thaw cycles. For in vitro assays, typical concentrations range from 10 nM to 1 µM depending on cell type and endpoint. For in vivo studies, dosing and administration routes should be calibrated based on animal model and target tissue proteasome activity. For detailed protocols and troubleshooting, refer to the APExBIO MG-262 product page and supplementary workflow guides.

Conclusion & Outlook

MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a gold-standard, reversible, and cell-permeable proteasome inhibitor. Its defined selectivity, robust activity, and compatibility with diverse research models make it an essential reagent for probing the UPS, studying cell cycle arrest, and mapping apoptosis signaling. With rising interest in the interplay between proteostasis, autophagy, and disease, MG-262 is poised to remain a cornerstone for mechanistic and translational research. For the latest protocols, benchmarks, and quality-tested material, APExBIO provides the authoritative source for MG-262 (A8179).